Skip to main content
. 2020 Oct 29;9:225–240. doi: 10.2147/ITT.S262566

Table 2.

Past and Current Status of GM-CSFR-Based Therapies

Drug Company Indication Phase Status ClinicalTrials.gov Identifier
Mavrilimumab Kiniksa RA I Completed NCT00771420
RA II Completed NCT01706926
RA II Completed NCT01715896
RA II Terminated NCT01712399
Giant cell arteritis II Active, not recruiting NCT03827018
COVID-19 II Recruiting NCT04399980
COVID-19 II Not yet recruiting NCT04397497

Abbreviation: RA, rheumatoid arthritis.